GV.PA Stock - Genomic Vision S.A.
Unlock GoAI Insights for GV.PA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $1.48M | $1.41M | $1.30M | $2.24M | $1.90M |
| Gross Profit | $1.27M | $807,000 | $508,000 | $1.27M | $1.58M |
| Gross Margin | 86.0% | 57.1% | 39.2% | 56.8% | 82.8% |
| Operating Income | $-6,122,000 | $-4,898,000 | $-5,118,000 | $-4,222,000 | $-6,897,000 |
| Net Income | $-6,776,000 | $-4,998,000 | $-5,606,000 | $-5,356,000 | $-6,898,000 |
| Net Margin | -457.8% | -353.7% | -432.2% | -239.2% | -362.3% |
| EPS | $-0.05 | $-0.10 | $-0.12 | $-0.19 | $-0.81 |
Genomic Vision Société Anonyme, a molecular diagnostics and technology company, engages in the development of single DNA detection tools for research and in vitro diagnostics in France. The company offers FiberVision, a molecular combing platform that helps in DNA analysis workflow; FiberComb, a molecular combing system, which stretches single DNA molecules onto a vinyl silane glass surface; FiberVision, a scanner that acquires high resolution images of the whole surface of the coverslip with a hands-off workflow; FiberStudio, a software, which detects hybridization signals and analyzes data to generate results and reporting; FiberPrep, a DNA extraction kit that delivers purified DNA solutions for molecular combing; and accessories, such as custom treated glass carriers and disposable DNA reservoirs for use with the MCS, as well as sample cartridges for scanners. It also provides FiberProbes for BRCA that is a set of Genomic Morse Codes for the detection of mutations occurring in hereditary breast and ovarian cancer; and hereditary nonpolyposis colorectal cancer Genomic Morse Code sets, which allows the identification and characterization of various structural variations, including anomalies occurring in flanking regions of the MMR genes. In addition, the company offers combing services that allow customers to validate the planned gene editing events; detect incorrect events larger than 1kb, including incorrect deletions, insertions, or inversions; and quantify off-target/on-target ratios. It has a strategic alliance with Quest Diagnostics; and development agreement with La Timone Hospital; research and development agreement with the Institut Pasteur. Genomic Vision Société Anonyme was founded in 2004 and is headquartered in Bagneux, France.
Visit WebsiteEarnings History & Surprises
GV.PAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2024 | Jun 27, 2024 | — | — | — | — |
Q1 2024 | Feb 29, 2024 | — | — | — | — |
Q4 2023 | Nov 14, 2023 | — | $-0.06 | — | — |
Q1 2023 | Feb 28, 2023 | — | $-0.05 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.03 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.05 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.05 | — | — |
Q1 2021 | Feb 19, 2021 | — | $-0.06 | — | — |
Q4 2020 | Nov 13, 2020 | — | $-0.06 | — | — |
Q2 2020 | May 30, 2020 | — | $-0.11 | — | — |
Q4 2019 | Nov 1, 2019 | — | $-0.08 | — | — |
Q2 2019 | May 2, 2019 | — | $-0.04 | — | — |
Q4 2018 | Oct 24, 2018 | — | $-0.41 | — | — |
Q1 2018 | Mar 21, 2018 | — | $-0.20 | — | — |
Q3 2017 | Jul 25, 2017 | — | $-0.92 | — | — |
Q1 2017 | Mar 1, 2017 | — | $-0.46 | — | — |
Q4 2016 | Oct 28, 2016 | — | $-0.97 | — | — |
Q2 2016 | May 9, 2016 | — | $-0.49 | — | — |
Q4 2015 | Oct 22, 2015 | — | $-0.49 | — | — |
Q2 2015 | Apr 30, 2015 | — | $-0.27 | — | — |
Latest News
Frequently Asked Questions about GV.PA
What is GV.PA's current stock price?
What is the analyst price target for GV.PA?
What sector is Genomic Vision S.A. in?
What is GV.PA's market cap?
Does GV.PA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to GV.PA for comparison